Financing ·
Calidi Biotherapeutics, Inc. closed a registered direct offering on September 21, 2026, selling 1,025,640 shares of…
CLDICalidi Biotherapeutics, Inc.
Calidi Biotherapeutics, Inc. closed a registered direct offering on September 21, 2026, selling 1,025,640 shares of common stock at $1.17 per share to generate approximately $1.2 million in gross proceeds. The company intends to use the net proceeds for working capital and general corporate purposes. No underwriter or placement agent was involved in the transaction. Calidi Biotherapeutics operates as a biotechnology company pioneering targeted genetic medicines using its RedTail platform.